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Intensive versus conventional glucose control in critically Ill patients
Abstract
Background The optimal target range for blood glucose in critically ill patients remains unclear. Methods
Within 24 hours after admission to an intensive care unit(ICU), adults who were expected to require
treatment in the ICU on 3 or more consecutive days were randomly assigned to undergo either intensive
glucose control, with a target blood glucose range of 81 to 108 mg per deciliter(4.5 to 6.0 mmol per liter), or
conventional glucose control, with a target of 180 mg or less per deciliter(10.0 mmol or less per liter). We
defined the primary end point as death from any cause within 90 days after randomization. Results Of the
6104 patients who underwent randomization, 3054 were assigned to undergo intensive control and 3050 to
undergo conventional control; data with regard to the primary outcome at day 90 were available for 3010 and
3012 patients, respectively. The two groups had similar characteristics at baseline. A total of 829
patients(27.5%) in the intensive-control group and 751(24.9%) in the conventional-control group died(odds
ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 1.28; P=0.02). The treatment effect did not
differ significantly between operative(surgical) patients and nonoperative(medical) patients(odds ratio for
death in the intensive-control group, 1.31 and 1.07, respectively; P = 0.10). Severe hypoglycemia(blood
glucose level, <40 mg per deciliter>[2.2 mmol per liter]) was reported in 206 of 3016 patients(6.8%) in the
intensive-control group and 15 of 3014(0.5%) in the conventional-control group(P<0.001). There was no
significant difference between the two treatment groups in the median number of days in the ICU(P = 0.84)
or hospital(P = 0.86) or the median number of days of mechanical ventilation(P = 0.56) or renal-replacement
therapy(P=0.39). Conclusions In this large, international, randomized trial, we found that intensive glucose
control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter
resulted in lower mortality than did a target of 81 to 108 mg per deciliter.(ClinicalTrials.gov number,
NCT00220987.) Copyright © 2009 Massachusetts Medical Society.
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Background
The optimal target range for blood glucose in critically ill patients remains unclear.
Methods
Within 24 hours after admission to an intensive care unit (ICU), adults who were 
expected to require treatment in the ICU on 3 or more consecutive days were ran-
domly assigned to undergo either intensive glucose control, with a target blood 
glucose range of 81 to 108 mg per deciliter (4.5 to 6.0 mmol per liter), or conven-
tional glucose control, with a target of 180 mg or less per deciliter (10.0 mmol or 
less per liter). We defined the primary end point as death from any cause within 90 
days after randomization.
Results
Of the 6104 patients who underwent randomization, 3054 were assigned to un-
dergo intensive control and 3050 to undergo conventional control; data with regard 
to the primary outcome at day 90 were available for 3010 and 3012 patients, respec-
tively. The two groups had similar characteristics at baseline. A total of 829 patients 
(27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control 
group died (odds ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 
1.28; P = 0.02). The treatment effect did not differ significantly between operative 
(surgical) patients and nonoperative (medical) patients (odds ratio for death in the 
intensive-control group, 1.31 and 1.07, respectively; P = 0.10). Severe hypoglycemia 
(blood glucose level, ≤40 mg per deciliter [2.2 mmol per liter]) was reported in 206 
of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the 
conventional-control group (P<0.001). There was no significant difference between 
the two treatment groups in the median number of days in the ICU (P = 0.84) or hos-
pital (P = 0.86) or the median number of days of mechanical ventilation (P = 0.56) or 
renal-replacement therapy (P = 0.39).
Conclusions
In this large, international, randomized trial, we found that intensive glucose con-
trol increased mortality among adults in the ICU: a blood glucose target of 180 mg 
or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per 
deciliter. (ClinicalTrials.gov number, NCT00220987.)
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Hyperglycemia is common in acute-ly ill patients, including those treated in intensive care units (ICUs).1 The occur-
rence of hyperglycemia, in particular severe hyper-
glycemia, is associated with increased morbidity 
and mortality in a variety of groups of patients,2-5 
but trials examining the effects of tighter glucose 
control have had conflicting results.6-13 Systematic 
reviews and meta-analyses have also led to differ-
ing conclusions.14,15 Nevertheless, many profes-
sional organizations recommend tight glucose con-
trol for patients treated in ICUs.16,17
Barriers to widespread adoption of tight glucose 
control include the increased risk of severe hypo-
glycemia,14 concerns about the external validity of 
some studies,18,19 the difficulty in achieving nor-
moglycemia in critically ill patients,20,21 and the 
increased resources that would be required.22 Be-
cause of these issues and uncertainty about the 
balance of risks and benefits, tight glucose con-
trol is used infrequently by some clinicians.23,24 
We designed the Normoglycemia in Intensive Care 
Evaluation–Survival Using Glucose Algorithm Reg-
ulation (NICE-SUGAR) trial to test the hypothesis 




We conducted a parallel-group, randomized, con-
trolled trial involving adult medical and surgical 
patients admitted to the ICUs of 42 hospitals: 38 
academic tertiary care hospitals and 4 community 
hospitals. Eligible patients were those expected to 
require treatment in the ICU on 3 or more consecu-
tive days (see Appendix A in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org). A detailed description of the study 
was published previously.25
The study was approved by the ethics commit-
tees of the University of Sydney, the University of 
British Columbia, and each participating institu-
tion. Written informed consent, obtained before 
randomization, or delayed consent was obtained 
from each patient or from a legal surrogate.
Study participants were randomly assigned to 
glucose control with one of two target ranges: the 
intensive (i.e., tight) control target of 81 to 108 mg 
per deciliter (4.5 to 6.0 mmol per liter), based on 
that used in previous studies,12,13 or a conven-
tional-control target of 180 mg or less per deci-
liter (10.0 mmol or less per liter), based on practice 
surveys in Australia, New Zealand, and Cana-
da.23,25 Randomization was stratified according 
to type of admission (operative or nonoperative) 
and region (Australia and New Zealand or North 
America). Patients were randomly assigned to a 
treatment group by the clinicians treating them 
or by local study coordinators, with the use of a 
minimization algorithm26 accessed through a se-
cure Web site. The treatment assignments were 
concealed before randomization, but subsequently, 
clinical staff were aware of them.
Control of blood glucose was achieved with the 
use of an intravenous infusion of insulin in saline. 
In the group of patients assigned to undergo con-
ventional glucose control, insulin was adminis-
tered if the blood glucose level exceeded 180 mg 
per deciliter; insulin administration was reduced 
and then discontinued if the blood glucose level 
dropped below 144 mg per deciliter (8.0 mmol per 
liter). Blood glucose levels in each patient were 
managed as part of the normal duties of the clini-
cal staff at the participating center. In both groups, 
this management was guided by treatment algo-
rithms accessed through a secure Web site (for 
de tails of the treatment algorithm, see https://
studies.thegeorgeinstitute.org/nice/).
The trial intervention was discontinued once 
the patient was eating or was discharged from the 
ICU but was resumed if the patient was readmit-
ted to the ICU within 90 days. It was discontinued 
permanently at the time of death or 90 days after 
randomization, whichever occurred first.
Blood samples for glucose measurement were 
obtained by means of arterial catheters whenever 
possible; the use of capillary samples was discour-
aged. Blood glucose levels were measured with the 
use of point-of-care or arterial blood gas analyz-
ers or laboratory analyzers in routine use at each 
center. All other aspects of patient care, including 
nutritional management, were carried out at the 
discretion of the treating clinicians.
Assessments and Data Collection at Baseline
Local study coordinators at each institution col-
lected the data; source data were verified by study 
monitors from regional coordinating centers. At 
baseline, demographic and clinical characteristics, 
including the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score27 (which can range 
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from 0 to 71, with higher scores indicating more 
severe illness) and the diagnostic criteria for se-
vere sepsis,28 were collected. Admissions to the ICU 
directly from the operating or recovery room were 
classified as operative admissions. Patients were 
classified as having diabetes on the basis of their 
medical history and were classified as having trau-
ma if the ICU admission occurred within 48 hours 
after admission to the hospital for trauma. Previ-
ous treatment with corticosteroids was defined 
as treatment with systemic corticosteroids for 72 
hours or more immediately before randomization.
From the time of randomization to the time of 
discharge from the ICU or 90 days after random-
ization (whichever came first), we recorded all 
blood glucose measurements, insulin administra-
tion, red-cell administration, blood cultures that 
were positive for pathogenic organisms, type and 
volume of all enteral and parenteral nutrition and 
additional intravenous glucose administered, and 
corticosteroid administration. Also recorded were 
the cardiovascular, respiratory, renal, hepatic, and 
hematologic components of the Sequential Organ 
Failure Assessment (SOFA, for which scores can 
range from 0 to 4 for each organ system, with 
higher scores indicating more severe dysfunc-
tion)29 and the use of mechanical ventilation and 
renal-replacement therapy.
Outcome Measures
Outcome measures and statistical analyses were 
defined in a prespecified statistical-analysis plan.30 
The primary outcome measure was death from any 
cause within 90 days after randomization, in an 
analysis that was not adjusted for baseline char-
acteristics. Secondary outcome measures were sur-
vival time during the first 90 days, cause-specific 
death (see Appendix C in the Supplementary Ap-
pendix for more information), and durations of 
mechanical ventilation, renal-replacement therapy, 
and stays in the ICU and hospital. Tertiary out-
comes were death from any cause within 28 days 
after randomization, place of death (ICU, hospital 
ward, or other), incidence of new organ failure, 
positive blood culture, receipt of red-cell transfu-
sion, and volume of the transfusion.
The primary outcome was also examined in six 
predefined pairs of subgroups: operative patients 
and nonoperative patients, patients with and those 
without diabetes, patients with and those without 
trauma, patients with and those without severe 
sepsis, patients treated and those not treated with 
corticosteroids, and patients whose APACHE II 
score was 25 or more and those whose score was 
less than 25.30
Serious Adverse Events
A blood glucose level of 40 mg per deciliter (2.2 
mmol per liter) or less was considered a serious 
adverse event. When the blood glucose level was 
measured with a bedside point-of-care analyzer, 
we requested that the treating clinician obtain a 
blood sample for laboratory confirmation before 
treating the presumed hypoglycemia. The details 
of each event were reviewed by the two study man-
agement committees and submitted to the research 
ethics committees of all participating centers and 
to the independent data and safety monitoring 
committee.
Statistical Analysis
The study was originally designed to enroll 4000 
patients. On the basis of data reported by Van den 
Berghe et al. in 2006,13 the sample size was in-
creased to 6100, thereby providing a statistical 
power of 90% to detect an absolute difference in 
mortality between the two groups of 3.8 percent-
age points, assuming a baseline mortality of 30% 
at a two-sided alpha level of less than 0.05. All 
data were analyzed according to the intention-to-
treat principle, with no imputation for missing 
values. The primary analysis for death at 90 days 
was performed with the use of an unadjusted chi-
square test. A secondary analysis based on logis-
tic regression was also conducted, with the strata 
used for randomization (type of admission and 
geographic region) as covariates, as well as age, 
location before ICU admission, APACHE II score, 
and use or nonuse of mechanical ventilation at 
baseline. Other binary end points were analyzed 
by means of a chi-square test or Fisher’s exact test. 
Continuous variables were compared with the use 
of unpaired t-tests, Welch’s tests, or Wilcoxon rank-
sum tests. All odds ratios and their correspond-
ing 95% confidence intervals were calculated ac-
cording to the profile-likelihood method. The time 
from randomization to death in the two treatment 
groups was compared with the use of the log-rank 
test, and the results are presented as Kaplan–Meier 
curves. Hazard ratios were obtained from Cox 
models. The time-weighted blood glucose level 
(with weighting based on the time difference be-
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tween two consecutive measurements applied to 
the average of the two consecutive measurements) 
was computed for all patients for whom data were 
available.
Subgroup analyses for the primary outcome 
were based on an unadjusted test of interaction in 
a logistic model. Estimated distributions of indi-
vidual patients’ average time-weighted blood glu-
cose levels, according to treatment group, were 
obtained by fitting generalized lambda distribu-
tions with the use of the method of maximum 
likelihood.31,32 All analyses were conducted with 
the use of S-PLUS software (version 8.0) and 
R software (version 2.7.0), and the results were 
verified independently with SAS software (ver-
sion 9.1). The data were analyzed by the Statisti-
cal Services Division of the George Institute for 
International Health (University of Sydney).
Two preplanned interim analyses were per-
formed by an independent statistician when 1500 
and 4000 of the 6100 patients (25% and 66%, re-
spectively) reached the 90th day of follow-up. The 
analyses were reviewed by the independent data 
and safety monitoring committee, which was 
charged with recommending that the trial be 
stopped if there was evidence beyond a reasonable 
doubt of a difference in the rate of death from any 
cause between the two treatment groups. Since a 
difference of 3 SE was used as a guideline to rec-
ommend early stopping, the final mortality anal-
ysis was conducted with an alpha of 0.048.
R esult s
Study Participants
Participants were recruited and had follow-up dur-
ing the period from December 2004 through No-
vember 2008; 6104 were randomly assigned to one 
of the two treatment groups: 3054 to intensive glu-
cose control and 3050 to conventional glucose con-
trol (Fig. 1). Where delayed consent was permitted, 
every patient or a legal surrogate was approached 
for consent. Delayed consent to the use of study-
related data was withheld, or previously obtained 
consent was withdrawn, for 38 of the 3054 patients 
(1.2%) assigned to intensive control and 36 of the 
3050 patients (1.2%) assigned to conventional con-
trol; thus, study data were available for 3016 and 
3014 patients, respectively. At 90 days, an addi-
tional six patients (0.2%) in the intensive-control 
group and two (0.1%) in the conventional-control 
group were lost to follow-up. Of the 6030 patients 
for whom study data were available, 5275 (87.5%) 
were recruited in Australia or New Zealand.
The baseline characteristics of the treatment 
groups were similar (Table 1). The mean (±SD) 
age was 60.4±17.2 and 59.9±17.1 years in the in-
tensive-control group and the conventional-con-
trol group, respectively; the percentage of male 
patients, 62.6% and 64.2%; the mean APACHE II 
score, 21.1±7.9 and 21.1±8.3; and the percentage 
of operative admissions, 36.9% and 37.2%. 
The assigned study treatment, intensive or con-
ventional blood glucose management according to 
the study-treatment algorithm, was administered 
to 5997 of 6030 patients (99.5%): 2998 of 3016 
(99.4%) in the intensive-control group and 2999 of 
3014 (99.5%) in the conventional-control group. 
The median duration of study treatment was 4.2 
days (interquartile range, 1.9 to 8.7) in the in-
tensive-control group and 4.3 days (interquartile 
range, 2.0 to 9.0) in the conventional-control group 
(P = 0.69). 
Study treatment was discontinued prematurely 
in 304 of 3054 patients (10.0%) in the intensive-
control group and 225 of 3050 patients (7.4%) in 
the conventional-control group. Reasons for dis-
continuation were withdrawal because of a request 
by the patient or surrogate (26 patients [0.9%] as-
signed to intensive control and 22 patients [0.7%] 
assigned to conventional control) or by the treat-
ing physician (115 patients [3.8%] and 48 patients 
[1.6%], respectively), because of serious adverse 
events (13 patients [0.4%] and 1 patient [<0.1%], 
respectively), because of a change in the focus of 
treatment to palliative care (116 patients [3.8%] 
and 115 patients [3.8%], respectively), and mis-
cellaneous reasons (34 patients [1.1%] and 39 pa-
tients [1.3%], respectively).
At the completion of the trial, data on vital 
status 90 days after randomization were unavail-
able for 82 of 6014 patients (1.4%), 44 in the in-
tensive-control group and 38 in the convention-
al-control group. For 74 of these patients, the 
vital-status data were missing because consent had 
been withheld or withdrawn (Fig. 1).
Insulin Administration and Treatment 
Effects
Patients undergoing intensive glucose control were 
more likely than those undergoing conventional 
control to have received insulin (2931 of 3014 pa-
tients [97.2%] vs. 2080 of 3014 [69.0%], P<0.001), 
and they received a larger mean insulin dose 
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(50.2±38.1 units per day, vs. 16.9±29.0 with con-
ventional control; P<0.001) (Table 2). The mean 
time-weighted blood glucose level was significantly 
lower in the intensive-control group than in the 
conventional-control group (115±18 vs. 144±23 mg 
per deciliter [6.4±1.0 vs. 8.0±1.3 mmol per liter], 
P<0.001). Additional measures of glycemic control 
are shown in Table 2 and Figures 2A and 2B.
Nutrition and Concomitant Treatment
During the first 14 days after randomization, the 
mean daily amount of nonprotein calories admin-
33p9
6104 Underwent randomization
40,171 Patients were assessed for eligibility
and met inclusion criteria
31,675 Were ineligible
12,733 Were expected to be eating the next day
7,107 Were in an ICU >24 hr
3,134 Were expected to die imminently
1,634 Could not provide consent before ran-
domization and had no surrogate who
could, and delayed consent was not per-
mitted, according to local regulations
7,067 Met other exclusion criteria
2392 Were eligible but were excluded
1094 Had objection from treating clinician
1202 Declined to participate
96 Were excluded for unknown reason
3054 Were assigned to undergo
intensive glucose control
3050 Were assigned to undergo
conventional glucose control
304 (10.0%) Discontinued inter-
vention
26 (0.9%) Were withdrawn
because of patient’s
or surrogate’s request
115 (3.8%) Were withdrawn
because of physician’s
request
116 (3.8%) Were switched to
palliative care
34 (1.1%) Had other reason
13 (0.4%) Were withdrawn
because of serious adverse
event
44 (1.4%) Were lost to follow-up
38 (1.2%) Withdrew or with-
held consent
6 (0.2%) Could not be located
225 (7.4%) Discontinued inter-
vention
22 (0.7%) Were withdrawn
because of patient’s
or surrogate’s request
48 (1.6%) Were withdrawn
because of physician’s
request
115 (3.8%) Were switched to
palliative care
39 (1.3%) Had other reason
1 (<0.1%) Were withdrawn
because of serious adverse
event
38 (1.2%) Were lost to follow-up
36 (1.2%) Withdrew or with-
held consent
2 (0.1%) Could not be located
3016 (98.8%) Had data included
in the analysis
3010 (98.6%) Had 90-day data
3014 (98.8%) Had data included
in the analysis
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Figure 1. Assessment, Randomization, and Follow-up of the Study Patients.
A total of 14 of the expected 1132 monthly screening logs (1.2%) were not received at the coordinating center. ICU 
denotes intensive care unit.
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istered was 891±490 kcal in the intensive-control 
group and 872±500 kcal in the conventional-con-
trol group (P = 0.14). Of this amount, 624±496 kcal 
(70.0%) and 623±496 kcal (71.4%), respectively, 
were given as enteral nutrition; 173±359 kcal 
(19.4%) and 162±345 kcal (18.6%) as parenteral nu-
trition; and 93.4±88.8 kcal (10.5%) and 87.2±93.5 
kcal (10.0%) as intravenous glucose (Table 2, and 
Appendix B in the Supplementary Appendix).
After randomization, more patients in the in-
tensive-control group than in the conventional-
control group were treated with corticosteroids 
(1042 of 3010 [34.6%] vs. 955 of 3009 [31.7%], 
P = 0.02). The median time from randomization to 
Table 1. Baseline Characteristics of the Study Patients.*
Variable Intensive Glucose Control Conventional Glucose Control
Age — yr 60.4±17.2 59.9±17.1
Female sex — no./total no. (%) 1128/3016 (37.4) 1079/3014 (35.8)
Weight — kg 80.7±21.4 80.9±21.2
Body-mass index† 27.9±7.7 28.0±7.2
Interval from ICU admission to randomization — hr 13.4±7.6 13.4±7.7
Reason for ICU admission — no./total no. (%)
Operative 1112/3015 (36.9) 1121/3014 (37.2)
Nonoperative 1903/3015 (63.1) 1893/3014 (62.8)
Location before ICU admission — no./total no. (%)
Emergency department 718/3015 (23.8) 749/3014 (24.9)
Hospital floor (or ward)
Without previous ICU admission 640/3015 (21.2) 618/3014 (20.5)
With previous ICU admission 42/3015 (1.4) 30/3014 (1.0)
Another ICU 125/3015 (4.1) 102/3014 (3.4)
Another hospital 445/3015 (14.8) 453/3014 (15.0)
Operating room
After emergency surgery 682/3015 (22.6) 671/3014 (22.3)
After elective surgery 363/3015 (12.0) 391/3014 (13.0)
APACHE II score 21.1±7.91 21.1±8.3
Blood glucose level — mg/dl 146±52.3 144±49.1
Organ failure or dysfunction — no./total no. (%)
Respiratory
Dysfunction (SOFA score, 1–2) 1207/2993 (40.3) 1222/2990 (40.9)
Failure (SOFA score, 3–4) 1526/2993 (51.0) 1521/2990 (50.9)
Coagulatory
Dysfunction (SOFA score, 1–2) 947/2987 (31.7) 874/2989 (29.2)
Failure (SOFA score, 3–4) 128/2987 (4.3) 137/2989 (4.6)
Hepatic
Dysfunction (SOFA score, 1–2) 831/2807 (29.6) 834/2802 (29.8)
Failure (SOFA score, 3–4) 70/2807 (2.5) 50/2802 (1.8)
Cardiovascular
Dysfunction (SOFA score, 1–2) 583/3011 (19.4) 614/3012 (20.4)
Failure (SOFA score, 3–4) 1726/3011 (57.3) 1695/3012 (56.3)
Renal
Dysfunction (SOFA score, 1–2) 1042/2981 (35.0) 1071/2974 (36.0)
Failure (SOFA score, 3–4) 249/2981 (8.4) 228/2974 (7.7)
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commencement of corticosteroid treatment was 
0 days (interquartile range, 0 to 1) in both groups 
(P = 0.34). The most common indication for cor-
ticosteroid administration in both groups was the 
treatment of septic shock, occurring in 376 of the 
1042 patients in the intensive-control group (36.1%) 
who received corticosteroids, as compared with 
328 of the 955 patients in the conventional-con-
trol group (34.3%) (absolute difference, 1.7 per-
centage points; 95% confidence interval [CI], −2.5 
to 5.9; P = 0.42) (Table 2).
Outcomes
Ninety days after randomization, 829 of 3010 pa-
tients (27.5%) in the intensive-control group had 
died, as compared with 751 of 3012 patients (24.9%) 
in the conventional-control group (Table 3). The 
absolute difference in mortality was 2.6 percent-
age points (95% CI, 0.4 to 4.8), and the odds ratio 
for death with intensive control was 1.14 (95% CI, 
1.02 to 1.28; P = 0.02). The difference in mortality 
between the two treatment groups was still sig-
nificant after adjustment for the predefined base-
line risk factors (adjusted odds ratio, 1.14; 95% CI, 
1.01 to 1.29; P = 0.04). The median survival time 
was lower in the intensive-control group than in 
the conventional-control group (hazard ratio, 1.11; 
95% CI, 1.01 to 1.23; P = 0.03) (Fig. 3A).
Overall, the distributions of proximate causes 
of death were similar in the two groups (P = 0.12) 
(Table 3). However, deaths from cardiovascular 
causes were more common in the intensive-con-
trol group (345 of 829 patients [41.6%]) than in 
the conventional-control group (269 of 751 pa-
tients [35.8%]) (absolute difference, 5.8 percentage 
points; P = 0.02). In the intensive-control group and 
the conventional-control group, the majority of 
deaths occurred in the ICU (546 of 829 patients 
[65.9%] and 498 of 751 patients [66.3%], respec-
tively) or in the hospital after discharge from the 
ICU (220 of 829 patients [26.5%] and 197 of 751 
patients [26.2%], respectively). The remaining 
deaths (63 of 829 patients [7.6%] undergoing in-
tensive control and 56 of 751 patients [7.5%] un-
dergoing conventional control) occurred after 
hospital discharge. In both groups, potentially life-
sustaining treatments were withheld or withdrawn 
in more than 90% of the patients who died (see 
Appendix D in the Supplementary Appendix). 
During the 90-day study period, there was no 
significant difference between the two groups in 
the median length of stay in the ICU or hospital 
(Table 3). At 90 days, 7 of the 3016 patients (0.2%) 
in the intensive-control group and 6 of the 3014 
patients (0.2%) in the conventional-control group 
were still in the ICU (P = 0.78), and 174 patients 
(5.8%) and 166 patients (5.5%), respectively, were 
still in the hospital (P = 0.66).
The number of patients in whom new single 
or multiple organ failures developed were simi-
Table 1. (Continued.)
Variable Intensive Glucose Control Conventional Glucose Control
Mechanical ventilation — no./total no. (%) 2825/3014 (93.7) 2793/3014 (92.7)
Renal-replacement therapy — no./total no. (%) 179/3014 (5.9) 165/3014 (5.5)
History of diabetes mellitus — no./total no. (%) 615/3015 (20.4) 596/3014 (19.8)
Type I diabetes 50/615 (8.1) 42/596 (7.0)
Type II diabetes 565/615 (91.9) 554/596 (93.0)
Previous treatment with insulin 183/615 (29.8) 163/596 (27.3)
Previous treatment with systemic corticosteroids — no./total no. (%) 393/3014 (13.0) 378/3014 (12.5)
Subgroup classification — no./total no. (%)
Severe sepsis at randomization 676/3014 (22.4) 626/3014 (20.8)
Trauma 422/3014 (14.0) 466/3014 (15.5)
APACHE II score ≥25 929/3013 (30.8) 945/3012 (31.4)
* Plus–minus values are means ±SD. Acute Physiology and Chronic Health Evaluation II (APACHE II) scores can range from 0 to 71, with 
higher scores indicating more severe illness, and Sequential Organ Failure Assessment (SOFA) scores can range from 0 to 4 for each organ 
system, with higher scores indicating more severe organ dysfunction. Severe sepsis was defined according to the consensus-conference cri-
teria of the American College of Chest Physicians–Society of Critical Care Medicine.28 To convert the values for blood glucose to millimoles 
per liter, multiply by 0.05551. ICU denotes intensive care unit.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on August 5, 2013. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;13 nejm.org march 26, 20091290
Table 2. Blood Glucose Management and Levels, Calorie Administration, and Corticosteroid Treatment, According to Treatment Group.*
Variable
Total No.  






Absolute Difference  
(95% CI) Statistical Test P Value
percentage points
Treated with insulin — no./total no. (%) 6028 2931/3014 (97.2) 2080/3014 (69.0) 28.2 (26.5 to 30.0) Pearson’s test <0.001
Insulin dose — units/day 6028 50.2±38.1 16.9±29.0 33.3 (31.6 to 35.0) Welch’s test <0.001
Days on treatment algorithm — median 
(interquartile range)
5991 4.2 (1.9 to 8.7) 4.3 (2.0 to 9.0) −0.2 t-test 0.69
Morning blood glucose — mg/dl
From randomization to cessation of 
study treatment
6001 118±25 145±26 −27 (−28 to −25) Welch’s test <0.001
From randomization to ICU dis-
charge
5987 118±25 145±26 −27 (−28 to −25) Welch’s test <0.001
Time-weighted blood glucose — mg/dl
From randomization to cessation of 
study treatment
6014 115±18 144±23 −29 (−30 to −28) Welch’s test <0.001
From randomization to ICU dis-
charge
6000 115±19 144±23 −29 (−30 to −28) Welch’s test <0.001
Nonprotein calories administered on 
days 1–14 — kcal/day
By enteral route 624±496 623±496 2 (−24 to 27) Welch’s test 0.89
By parenteral route 173±359 162±345 11 (−7 to 29) Welch’s test 0.22
As intravenous glucose 93.4±88.8 87.2±93.5 6.3 (1.6 to 10.9) t-test 0.008
Total 891±490 872±500 19 (−6 to 44) t-test 0.14
Corticosteroid treatment —  
no./total no. (%)
6022 1042/3013 (34.6) 955/3009 (31.7) 2.9 (0.5 to 5.2) Pearson’s test 0.02
Interval from randomization to cortico-
steroid treatment — median  
(interquartile range)
1996 0 (0 to 1) 0 (0 to 1) 0 t-test 0.34
Indication for corticosteroids —  
no./total no. (%)†
1997 Pearson’s test
Replacement for previous cortico-
steroid treatment
168/1042 (16.1) 168/955 (17.6) −1.5 (−4.8 to 1.8) 0.38
Septic shock 376/1042 (36.1) 328/955 (34.3) 1.7 (−2.5 to 5.9) 0.42
Fibroproliferative ARDS 26/1042 (2.5) 17/955 (1.8) 0.7 (−0.6 to 2.0) 0.27
Immunosuppression for prevention 
or treatment of organ rejection 
40/1042 (3.8) 41/955 (4.3) −0.5 (−2.2 to 1.3) 0.61
Immunosuppression for treatment of 
inflammatory disease
73/1042 (7.0) 61/955 (6.4) 0.6 (−1.6 to 2.8) 0.58
Cerebral edema after neurosurgery 46/1042 (4.4) 43/955 (4.5) −0.1 (−1.9 to 1.7) 0.92
Acute exacerbation of COPD 98/1042 (9.4) 90/955 (9.4) −0.02 (−2.6 to 2.6) 0.99
Acute asthma 39/1042 (3.7) 32/955 (3.4) 0.4 (−1.2 to 2.0) 0.64
Other 256/1042 (24.6) 237/955 (24.8) −0.3 (−4.0 to 3.5) 0.90
* Plus–minus values are means ±SD. To convert the values for blood glucose to millimoles per liter, multiply by 0.05551. ARDS denotes acute 
respiratory distress syndrome, and COPD chronic obstructive pulmonary disease.
† The sum of the number of indications for corticosteroids is greater than the number of patients with data (the number of patients treated), 
since some patients had more than one indication.
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lar with intensive and conventional glucose con-
trol (P = 0.11) (Table 3). There was no significant 
difference between the two groups in the num-
bers of days of mechanical ventilation and renal-
replacement therapy or in the rates of positive 
blood cultures and red-cell transfusion (Table 3).
With respect to 90-day mortality, subgroup 
analyses suggested no significant difference in 
the treatment effect for the comparisons of op-
erative and nonoperative patients (P = 0.10), pa-
tients with and those without diabetes (P = 0.60), 
patients with and those without severe sepsis 
(P = 0.93), and patients with an APACHE II score 
of 25 or more and those with a score of less than 
25 (P = 0.84) (Fig. 3B). Tests for interaction indi-
cated a possible trend toward subgroup-specific 
treatment effects for patients with trauma as com-
pared with those without trauma (P=0.07) and for 
patients receiving corticosteroids at baseline as 
compared with those not receiving corticosteroids 
(P = 0.06).
Severe hypoglycemia (defined as a blood glu-
cose level ≤40 mg per deciliter [2.2 mmol per li-
ter]) was recorded in 206 of 3016 patients (6.8%) 
undergoing intensive glucose control, as compared 
with 15 of 3014 patients (0.5%) undergoing con-
ventional control (odds ratio, 14.7; 95% CI, 9.0 to 
25.9; P<0.001). The recorded number of episodes 
of severe hypoglycemia was 272 in the intensive-
control group, as compared with 16 in the con-
ventional-control group; 173 of all 288 episodes 
(60.1%) were confirmed by a laboratory measure-
ment, 112 (38.9%) were unconfirmed bedside 
readings, and 3 (1.0%) were of unknown confir-
mation status. No long-term sequelae of severe 
hypoglycemia were reported.
Discussion
In this large, international, randomized trial in-
volving adults in the ICU, we found that intensive 
glucose control, as compared with conventional 
glucose control, increased the absolute risk of death 
at 90 days by 2.6 percentage points; this repre-
sents a number needed to harm of 38. The dif-
ference in mortality remained significant after 
adjustment for potential confounders. Severe hy-
poglycemia was significantly more common with 
intensive glucose control.
In conducting our trial, we sought to ensure 
a high degree of internal and external validity by 
concealing treatment assignments before random-
ization, selecting a long-term outcome that is not 
subject to biased ascertainment, evaluating a num-
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Figure 2. Data on Blood Glucose Level, According to Treatment Group.
Panel A shows mean blood glucose levels. Baseline data are the averages of 
the last blood glucose measurement obtained before randomization; day 1 
data are the average levels from the time of randomization to the end of 
the day of randomization. The bars indicate the 95% confidence intervals. 
The dashed line indicates 108 mg per deciliter, the upper limit of the target 
range for intensive glucose control. Panel B shows the density plot for the 
mean time-weighted blood glucose levels for individual patients. The 
dashed lines indicate the modes (most frequent values) in the intensive-
control group (blue) and the conventional-control group (red), as well as 
the upper threshold for severe hypoglycemia (black). To convert the values 
for blood glucose to millimoles per liter, multiply by 0.05551.
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Odds Ratio or  
Absolute Difference 
(95% CI)† Statistical Test P Value
Death — no. of patients/total no. (%) Logistic regression
At day 90 829/3010 (27.5) 751/3012 (24.9) 1.14 (1.02 to 1.28) 0.02
At day 28 670/3010 (22.3) 627/3012 (20.8) 1.09 (0.96 to 1.23) 0.17
Potentially life-sustaining treatment limited  
or withheld before death — no. of pa-
tients/total no. (%)
746/816 (91.4) 669/741 (90.3) 1.15 (0.81 to 1.62) Logistic regression 0.44
Limited because death was imminent 527/816 (64.6) 459/741 (61.9) 1.12 (0.91 to 1.38) 0.28
Withheld because not appropriate 219/816 (26.8) 210/741 (28.3) 0.93 (0.74 to 1.16) 0.51
CPR as terminal event — no. of patients/total 
no. (%)
70/816 (8.6) 72/741 (9.7) 0.87 (0.62 to 1.23) Logistic regression 0.44
Days from randomization to limitation  
or withholding of potentially life- 
sustaining treatment — median (IQR)
6 (3 to 16) 6 (2 to 15) t-test 0.42
Proximate cause of death — no. of patients/
total no. (%)
Pearson’s test 0.12
Cardiovascular-distributive shock 168/829 (20.3) 140/751 (18.6)
Other cardiovascular 177/829 (21.4) 129/751 (17.2)
Neurologic 180/829 (21.7) 194/751 (25.8)
Respiratory 191/829 (23.0) 177/751 (23.6)
Other 113/829 (13.6) 111/751 (14.8)
Place of death — no. of patients/total no. (%)
ICU 546/829 (65.9) 498/751 (66.3)
Elsewhere in hospital 220/829 (26.5) 197/751 (26.2)
Outside hospital, after discharge 63/829 (7.6) 56/751 (7.5)
Severe hypoglycemia — no. of patients/total 
no. (%)
206/3016 (6.8) 15/3014 (0.5) 14.7 (9.0 to 25.9) Logistic regression <0.001
Days in ICU — median (IQR) 6 (2 to 11) 6 (2 to 11) 0 Log-rank test 0.84
Days in hospital — median (IQR) 17 (8 to 35) 17 (8 to 35) 0 Log-rank test 0.86
Mechanical ventilation — no. of patients/ 
total no. (%)
2894/3014 (96.0) 2872/3014 (95.3) 0.7 (−0.3 to 1.76) Pearson’s test 0.17
Days of mechanical ventilation 6.6±6.6 6.6±6.5 0 Wilcoxon rank-sum test 0.56
Renal-replacement therapy — no. of patients/
total no. (%)
465/3014 (15.4) 438/3014 (14.5) 0.9 (−0.9 to 2.7) Pearson’s test 0.34
Days of renal-replacement therapy 0.8±2.6 0.8±2.8 0 Wilcoxon rank-sum test 0.39
No. of new organ failures — no. of patients/
total no. (%)‡
Pearson’s test 0.11
0 1571/2682 (58.6) 1536/2679 (57.3)
1 790/2682 (29.5) 837/2679 (31.2)
2 263/2682 (9.8) 257/2679 (9.6)
3 44/2682 (1.6) 46/2679 (1.7)
4 11/2682 (0.4) 2/2679 (0.1)
5 3/2682 (0.1) 1/2679 (<0.1)
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nearly complete follow-up, and following a pre-
defined statistical-analysis plan.30 The manage-
ment of blood glucose levels was standardized — 
nearly all patients received their assigned treatment, 
the mean blood glucose levels differed signifi-
cantly between the two treatment groups during 
the 90-day study period, and the rate of severe 
hypoglycemia was low in comparison with the 
rates in other trials.
Limitations of our trial include the use of a 
subjective criterion — expected length of stay in 
the ICU — for inclusion, the inability to make 
treating staff and study personnel unaware of 
the treatment-group assignments, and achieve-
ment of a glucose level modestly above the target 
range in a substantial proportion of patients in 
the intensive-control group. We did not collect 
specific data to address potential biologic mech-
anisms of the trial interventions or their costs. 
On the basis of the results in the predefined pairs 
of subgroups, we cannot exclude the possibility 
that intensive glucose control may benefit some 
patients.
Our findings differ from those of a recent 
meta-analysis showing that intensive glucose con-
trol did not significantly alter mortality among 
critically ill adults.14 In keeping with the trials in-
cluded in the meta-analysis, patients in our trial 
who were assigned to intensive glucose control, as 
compared with those assigned to conventional 
control, had lower blood glucose levels, received 
more insulin, and had more episodes of severe 
hypoglycemia.14 A unique feature of our trial was 
the standardized, complex management of blood 
glucose made possible at multiple centers through 
a computerized treatment algorithm accessible on 
centralized servers. In addition, our patients re-
ceived predominantly enteral nutrition, consonant 
with current evidence-based feeding guidelines,33 
whereas a substantial proportion of the patients 
included in the meta-analysis received predomi-
nantly parenteral nutrition.14,34
Our trial had greater statistical power than 
previous trials, as well as a longer follow-up period 
than all but two trials in the meta-analysis. Thus, 
our results may be due to a specific effect of our 
treatment algorithm, may be most generalizable 
to patients receiving predominantly enteral nutri-
tion, or may reflect harm not apparent in trials 
with shorter follow-up and lower statistical power.
In our trial, more patients in the intensive-
control group than in the conventional-control 
group were treated with corticosteroids, and the 
excess deaths in the intensive-control group were 
predominantly from cardiovascular causes. These 
differences might suggest that reducing blood glu-
cose levels by the administration of insulin has 
adverse effects on the cardiovascular system.35,36 
However, our trial was not designed to examine 
such mechanisms; further research is needed to 
understand the increased mortality in our trial.







Odds Ratio or  
Absolute Difference 
(95% CI)† Statistical Test P Value
Temporary sequelae of severe hypoglycemia 
— no. of patients/total no. (%)
Neurologic 1/206 (0.5) 1/15 (6.7)
Cardiovascular 6/206 (2.9) 1/15 (6.7)
Other 6/206 (2.9) 0
Blood culture positive for pathogenic organ-
isms — no. of patients/total no. (%)
387/3014 (12.8) 372/3011 (12.4) Pearson’s test 0.57
Transfusion of packed red cells — no. of  
patients/total no. (%)
1268/3013 (42.1) 1246/3014 (41.3) Pearson’s test 0.56
Volume of packed cells transfused — ml 122±144 126±193 Wilcoxon rank-sum test 0.82
* Plus–minus values are means ±SD. CPR denotes cardiopulmonary resuscitation, ICU intensive care unit, and IQR interquartile range.
† Absolute differences (percentage points) are given for median days in the ICU or hospital, percentage of patients undergoing mechanical 
ventilation or renal-replacement therapy, and median days of mechanical ventilation or renal-replacement therapy; for all other measures, 
odds ratios are given.
‡ Organ failure was defined as a Sequential Organ Failure Assessment (SOFA) score of 3 or 4 for any individual organ system.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on August 5, 2013. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;13 nejm.org march 26, 20091294

























All deaths at day 90





































































AUTHOR, PLEASE NOTE: 
















































The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on August 5, 2013. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Intensive vs. Conventional Glucose Control in Critically Ill Patients
n engl j med 360;13 nejm.org march 26, 2009 1295
al.,12 intensive glucose control has been widely 
recommended16,17 on the assumption that treat-
ment aimed at normoglycemia will benefit pa-
tients. As noted in other fields of medicine,37 a 
clinical trial targeting a perceived risk factor (in 
this case, hyperglycemia) is a test of a complex 
strategy that may have profound effects beyond 
its effect on the risk factor (here, the blood glu-
cose level). Our findings suggest that a goal of 
normoglycemia for glucose control does not nec-
essarily benefit critically ill patients and may be 
harmful. Whether the harm we observed resulted 
from the reduced blood glucose level, increased 
administration of insulin, occurrence of hypogly-
cemia, methodologic factors specific to our trial, 
or other factors is unclear.
In conclusion, our trial showed that a blood 
glucose target of less than 180 mg per deciliter 
resulted in lower mortality than a target of 81 to 
108 mg per deciliter. On the basis of our results, 
we do not recommend use of the lower target in 
critically ill adults.
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Figure 3 (facing page). Probability of Survival and Odds 
Ratios for Death, According to Treatment Group.
Panel A shows Kaplan–Meier estimates for the proba-
bility of survival, which at 90 days was greater in the 
conventional-control group than in the intensive-con-
trol group (hazard ratio, 1.11; 95% confidence interval, 
1.01 to 1.23; P = 0.03). Panel B shows the odds ratios 
(and 95% confidence intervals) for death from any 
cause in the intensive-control group as compared with 
the conventional-control group, among all patients and 
in six predefined pairs of subgroups. The size of the 
symbols indicates the relative numbers of deaths. The 
Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score can range from 0 to 71, with higher 
scores indicating more severe organ dysfunction.
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Hobart, TAS, Australia — A. Bell, T. Field, R. McAllister, K. Marsden, A. Turner; Royal North Shore Hospital, Sydney — S. Ankers, S. Bird, S. 
Finfer, R. Lee, A. O’Connor, J. Potter, N. Ramakrishnan, R. Raper; St. George Hospital, Sydney — V. Dhiacou, K. Girling, A. Jovanovska, J. 
Myburgh; St. Vincent’s Hospital, Melbourne, VIC, Australia — N. Groves, J. Holmes, J. Santamaria, R. Smith; Sir Charles Gairdner Hospital, Perth, 
WA, Australia — S. Baker, B. Roberts; Wellington Hospital, Wellington, New Zealand — L. Andrews, R. Dinsdale, R. Fenton, D. Mackle, S. 
Mortimer; Western Hospital, Melbourne, VIC, Australia — C. French, L. Little, H. Raunow; Wollongong Hospital, Wollongong, NSW, Australia — M. 
Gales, F. Hill, S. Rachakonda, D. Rogan; NSW Institute of Trauma and Injury Management, Sydney — C. Allsop; Australian and New Zealand In-
tensive Care Research Centre, Melbourne, VIC, Australia — L. Higgins; University of Sydney (Faculty of Medicine), Kolling Institute, and Department of En-
docrinology, Royal North Shore Hospital, Sydney — B. Robinson; North American site investigators (alphabetically by institution) — Calgary 
Health Region, Calgary, AB, Canada — K. Champagne, C. Doig, L. Knox, P. Taylor, C. Wilson; Kingston General Hospital, Kingston, ON, Canada 
— J. Drover, S. Hammond, E. Mann, M. Myers, A. Robinson; Maisonneuve Rosemont Hospital, Montreal — J. Harvey, Y. Skrobik; Mayo 
Clinic, Rochester, MN — A. Baumgartner, L. Meade, N. Vlahakis; Mount Sinai Hospital, Toronto — C. Ethier, M. Kramer-Kile, S. Mehta; Ot-
tawa General Hospital, Ottawa — C. Gaudert, S. Kanji, T. McArdle, I. Watpool; St Joseph’s Healthcare, Hamilton, ON, Canada — F. Clarke, D. 
Cook, E. McDonald, A. Tkaczyk; St. Michael’s Hospital, Toronto — J. Marshall, J. Morrissey, K. Porretta, O. Smith, V. Wen; St. Paul’s Hospi-
tal, Vancouver, BC, Canada — B.J. Ashley, P. Dodek, S. Mans; Sunnybrook Health Sciences Centre, Toronto — B. Bojilov, K. Code, R. Fowler, N. 
Marinoff; Toronto General Hospital, Toronto — L. Chu, J. Granton, M. McGrath-Chong, M. Steinberg; Toronto Western Hospital, Toronto — N. 
Ferguson, S. Go, A. Matte, J. Rosenberg, J. Stevenson; University of Alberta Hospital, Edmonton, AB, Canada — M. Jacka, L. Sonnema; Van-
couver General Hospital, Vancouver, BC, Canada — R. Autio, D. Chittock, D. Davies, P. Ganz, M. Gardner, S. Logie, L. Smith; Vancouver Island 
Health Authority, VIC, BC, Canada — L. Atkins, F. Auld, M. Stewart, G. Wood.
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